Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor
- 15 August 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (16) , 3357-3365
- https://doi.org/10.1200/jco.2004.10.103
Abstract
Purpose To assess the antitumor efficacy of pharmacokinetically guided topotecan dosing in previously untreated patients with medulloblastoma and supratentorial primitive neuroectodermal tumors, and to evaluate plasma and CSF disposition of topotecan in these patients. Patients and Methods After maximal surgical resection, 44 children with previously untreated high-risk medulloblastoma were enrolled, of which 36 were assessable for response. The topotecan window consisted of two cycles, administered initially as a 30-minute infusion daily for 5 days, lasting 6 weeks. Pharmacokinetic studies were conducted on day 1 to attain a topotecan lactone area under the plasma concentration-time curve (AUC) of 120 to 160 ng/mL·h. After 10 patients were enrolled, the infusion was modified to 4 hours, with dosage individualization. Results Of 36 assessable patients, four patients (11.1%) had a complete response and six (16.6%) showed a partial response, and disease was stable in 17 patients (47.2%). Toxicity was mostly hematologic, with only one patient experiencing treatment delay. The target plasma AUC was achieved in 24 of 32 studies (75%) in the 30-minute infusion group, and in 58 of 93 studies (62%) in the 4-hour infusion group. The desired CSF topotecan exposure was achieved in seven of eight pharmacokinetic studies when the topotecan plasma AUC was within target range. Conclusion Topotecan is an effective agent against pediatric medulloblastoma in patients who have received no therapy other than surgery. Pharmacokinetically guided dosing achieved the target plasma AUC in the majority of patients. This drug warrants testing as part of standard postradiation chemotherapeutic regimens. Furthermore, these results emphasize the importance of translational research in drug development, which in this case identified an effective drug.Keywords
This publication has 38 references indexed in Scilit:
- Outcome for children with high stage medulloblastoma: Results of the pediatric oncology group 9031International Journal of Radiation Oncology*Biology*Physics, 2000
- Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the german prospective randomized trial hit ’91International Journal of Radiation Oncology*Biology*Physics, 2000
- Treatment of Children With Medulloblastomas With Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group StudyJournal of Clinical Oncology, 1999
- Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors.Journal of Clinical Oncology, 1995
- Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SIOP) and the (German) society of paediatric oncology (GPO): SIOP IIMedical and Pediatric Oncology, 1995
- Carboplatin in childhood brain tumors: A children's cancer study group phase II trialCancer, 1990
- The treatment of medulloblastomaJournal of Neurosurgery, 1990
- Medulloblastoma at the joint center for radiation therapy between 1968 and 1984.The influence of radiation dose on the patterns of failure and survivalCancer, 1988
- Efficacy of Vincristine and Cyclophosphamide in the Therapy of Recurrent MedulloblastomaNeurosurgery, 1986
- High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in childrenJournal of Neurosurgery, 1981